Hematology & Oncology

Robert Siegel, M.D., professor of medicine and director of hematology and oncology, and Nader Sadeghi, M.D., professor of surgery and director of head and neck surgery, were mentioned in a public statement by U.S. Rep. Sanford Bishop saying that, after chemotherapy and surgery, he is now…
Jeanny Aragon-Ching, M.D., assistant professor of medicine, was interviewed by Everyday Health for a story on whether certain genes may impact a person's chances of getting bladder cancer and whether the cancer may take on an aggressive form.
Christina Puchalski, M.D., professor of medicine and director of the GW Institute for Spirituality and Health, was interviewed by dailyRX for a story on how oncologists can better converse with their patients about death.
Naomi L. C. Luban, M.D., professor of Pediatrics, and Lori Luchtman-Jones, M.D., associate professor of Pediatrics, have secured funding from the National Heart, Lung, and Blood Institute (NHLBI), at the National Institutes of Health (NIH) for a new pediatric transfusion medicine and hematology…
Imad Tabbara, M.D., GW professor of Medicine, interviewed about whether bone marrow donors should be paid.
Khaled el-Shami, M.D., assistant professor of Medicine at the GW School of Medicine and Health Sciences was quoted in an article in The Washington Post about Republican presidential candidate Herman Cain overcoming stage IV colon cancer.
Dr. Khaled el-Shami, assistant professor of Medicine at the GW School of Medicine and Health Sciences, was quoted in a Voice of America article about Apple CEO Steve Job's death from pancreatic cancer.
WASHINGTON — Kristina Demas, a third year medical student at The George Washington University School of Medicine and Health Sciences, was recently selected to receive the 2011 Medical Student Rotation Award from the American Society of Clinical Oncology (ASCO) and Susan G. Komen for the Cure.
Jeanny Aragon-Ching, M.D. assistant professor of Medicine at The George Washington University School of Medicine and Health Sciences, says that the new drug denosumab is a welcome addition to the options available for treatment of metastatic prostate cancer.